BioCentury | Feb 16, 2015
Company News

J&J, Valneva deal

...Johnson’s Janssen’s Crucell Holland B.V. for EUR45 million ($51 million). The deal includes the vaccine Dukoral...
BioCentury | Feb 5, 2015
Financial News

Valneva raises EUR 45M

...& Co. The company is acquiring Crucell Sweden AB, which will give it rights to Dukoral...
BioCentury | Jul 21, 2011
Distillery Therapeutics

Indication: Gastrointestinal disease

...retinoic acid in conjunction with other vaccines to treat gastrointestinal infections. Johnson & Johnson markets Dukoral...
BioCentury | Oct 5, 2009
Company News

Crucell, MASTA Ltd. sales and marketing update

...market travel vaccines including Epaxal aluminum-free hepatitis A vaccine; Vivotif oral typhoid fever vaccine; and Dukoral...
BioCentury | Dec 8, 2008
Regulation

Tropical diseases pipeline

...NYSE:NVS; SWX:NOVN) Coartem artemether (A)/lumefantrine Malaria Approved ex-U.S.; under review in U.S. Crucell (Euronext:CRXL; NASDAQ:CRXL) Dukoral...
BioCentury | Dec 4, 2006
Strategy

Building a vaccines franchise

...4Q06; Asia: start Ph I 1Q07 Crucell Factor V blood protein Preclin Crucell Other technology Dukoral...
BioCentury | Dec 4, 2006
Strategy

PER.C6 perseverance

...Vaccin AB (Stockholm, Sweden) for E39.4 million ($50.5 million) in cash to get access to Dukoral...
...BPC from Acambis and more recently SBL Vaccin, which not only had the cholera vaccine Dukoral...
BioCentury | Dec 4, 2006
Company News

Crucell, SBL Vaccin AB deal

...CRXL acquired SBL for E39.4 million ($50.5 million) in cash. The deal gives CRXL Dukoral...
BioCentury | Nov 22, 2006
Financial News

Crucell to raise EUR 80 million, acquire SBL

...SBL (Stockholm, Sweden) for EUR 39.4 million ($50.5 million) in cash. The deal gives CRXL Dukoral...
BioCentury | May 10, 2004
Company News

Chiron, SBL Vaccin AB deal

...Dukoral , to prevent cholera and travelers' diarrhea. Under the deal, Chiron Vaccines will market Dukoral...
Items per page:
1 - 10 of 25